SNS-595 and methods of using the same

1. A method for treating ovarian cancer comprising administering to a patient having ovarian cancer a dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid.

2. The method of claim 1 wherein the dose is 10 mg/m 2 -100 mg/m 2 .

3. The method of claim 1 wherein the dose 30 mg/m 2 -75 mg/m 2 .

4. The method of claim 1 wherein the dose is 40 mg/m 2 -80 mg/m 2 .

5. The method of claim 1 wherein the dose is 50 mg/m 2 -90 mg/m 2 .

6. The method of claim 1 additionally comprising administering to said patient a therapeutically effective dose of a supportive care agent.

7. The method of claim 6 wherein the supportive care agent is an antiemetic.

8. A method for treating ovarian cancer comprising: i) administering a dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a patient having ovarian cancer; ii) waiting a period of at least one day where the patient is not administered any (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid; iii) administering another dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to the patient.

9. The method of claim 8 wherein the period is at least 2 days.

10. The method of claim 8 wherein the period is at least 3 days.

11. The method of claim 8 wherein the period is at least 6 days.

12. The method of claim 8 wherein the period is at least 13 days.

13. The method of claim 7 wherein the period is at least 20 days.

14. The method of claim 7 wherein the period is at least 27 days.

15. A method for treating ovarian cancer comprising administering a weekly dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a patient having ovarian cancer.

16. A method for treating ovarian cancer comprising administering a dose of 10 mg/m 2 -150 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid once every three weeks to a patient having ovarian cancer.

17. A method for treating ovarian cancer comprising a cycle wherein the cycle comprises administering a dose of 50 mg/m 2 -110 mg/m 2 of (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid to a subject having ovarian cancer once every week for three weeks followed by a period of at least two weeks where no (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid is administered to said subject.